Target. Test. Treat: Patient-Derived Organoids Enable Smarter Evaluation of ADCs
12:15 pm - Tuesday 9th March 2027
- PDOs act as functional ADC patient avatars, preserving tumour heterogeneity and normal tissue biology to reflect clinical efficacy and on-target/ off-target toxicity
- PDOs capture variability in ADC response beyond antigen expression, enabling assessment of target engagement, internalisation, payload sensitivity, and tissue penetration
- PDOs enable the development of next-generation therapeutic strategies, allowing for testing of combination therapies and comparison with SoC data in patient relevant models